Shanghai Pharmaceuticals Holding Co (HKSE:02607) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Pharmaceuticals Holding Co EBITDA Margin % Related Terms
Shanghai Pharmaceuticals Holding Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co EBITDA Margin % Chart
HKSE:02607 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (HKSE:02607) has a EBITDA Margin % of 3.68% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. This is 28% below median its historical median of 5.10. Over the past decade, Shanghai Pharmaceuticals Holding Co's EBITDA Margin % has ranged from 4.05 to 5.59. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #63 out of 117 companies in the Medical Distribution industry, placing it in the top 53.8%.
Is Shanghai Pharmaceuticals Holding Co's EBITDA Margin % too high?
Shanghai Pharmaceuticals Holding Co's current EBITDA Margin % of 3.68% is 28% below median its 10-year median of 5.10. Over the past 10 years, this metric has ranged from a low of 4.05 to a high of 5.59. The Medical Distribution industry median EBITDA Margin % is 4.28. Shanghai Pharmaceuticals Holding Co's value of 3.68% is 14% below this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #63 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #63 out of 117 companies for EBITDA Margin %. This places Shanghai Pharmaceuticals Holding Co in the lower half of its industry. The industry median EBITDA Margin % is 4.28. Shanghai Pharmaceuticals Holding Co's value of 3.68% is 14% below this benchmark. Historically, Shanghai Pharmaceuticals Holding Co's own EBITDA Margin % has ranged from 4.05 to 5.59 over the past decade. While the company's 10-year median is 5.10 vs. the industry median of 4.28, Shanghai Pharmaceuticals Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current EBITDA Margin % of 3.68% is 14% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current EBITDA Margin % is 3.68%, which is 28% below median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (HKSE:02607) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$14.54, compared to a current price of HK$11.40 — trading 21.6% below its estimated fair value. The current EBITDA Margin % is 3.68%, which is 28% below median its 10-year median of 5.10 and 14% below the Medical Distribution industry median of 4.28. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (HKSE:02607), the current EBITDA Margin % is 3.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (HKSE:02607) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of HK$11.40 is trading 21.6% below its estimated GF Value™ of HK$14.54.
GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.
Key valuation signals for HKSE:02607:
EBITDA Margin %: 3.68% (28% below median its 10-year median of 5.10)
GF Value™: HK$14.54 vs. price of HK$11.40 (21.6% below fair value)
Industry Position: 14% below the Medical Distribution median (#63 of 117)
No single metric tells the full story. See the HKSE:02607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
87GF Score
Get the complete analysis for HKSE:02607
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02607 has been successfully added to your 
